The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study

被引:15
作者
Aguiar, Maira [1 ,2 ,7 ]
Bidaurrazaga Van-Dierdonck, Joseba [3 ]
Mar, Javier [4 ,5 ,6 ]
Stollenwerk, Nico [1 ,2 ]
机构
[1] Basque Ctr Appl Math BCAM, Bilbao, Spain
[2] Univ Trento, Dipartimento Matemat, Trento, Italy
[3] Publ Hlth, Basque Hlth Dept, Rekalde Zumarkalea 39A, Bilbao 48008, Spain
[4] Osakidetza Basque Hlth Serv, Res Unit, Debagoiena Integrated Healthcare Org, Guipuzcoa, Spain
[5] Biodonostia Hlth Res Inst, Donostia San Sebastian, Guipuzcoa, Spain
[6] Kronikgune Inst Hlth Serv Res, Econ Evaluat Unit, Baracaldo, Spain
[7] Ikerbasque, Basque Fdn Sci, Bilbao, Spain
基金
欧盟地平线“2020”;
关键词
COVID-19; Mathematical modeling; Vaccine efficacy; Vaccine coverage; Asymptomatic infection; SYSTEM;
D O I
10.1016/j.jare.2021.10.012
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction: Different COVID-19 vaccine efficacies are reported, with remarkable effectiveness against severe disease. The so called sterilizing immunity, occurring when vaccinated individuals cannot trans -mit the virus, is still being evaluated. It is also unclear to what extent people with no symptoms or mild infection transmit the disease, and estimating their contribution to outbreaks is challenging. Objective: With an uneven roll out of vaccination, the purpose of this study is to investigate the role of mild and asymptomatic infections on COVID-19 vaccine performance as vaccine efficacy and vaccine cov-erage vary. Methods: We use an epidemiological SHAR (Susceptible-Hospitalized-Asymptomatic-Recovered) model framework to evaluate the effects of vaccination in different epidemiological scenarios of coverage and efficacy. Two vaccination models, the vaccine V1 protecting against severe disease, and the vaccine V2, protecting against infection as well as severe disease, are compared to evaluate the reduction of overall infections and hospitalizations. Results: Vaccine performance is driven by the ability of asymptomatic or mild disease cases transmitting the virus. Vaccines protecting against severe disease but failing to block transmission might not be able to reduce significantly the severe disease burden during the initial stage of a vaccination roll out programme, with an eventual increase on the number of overall infections in a population. Conclusion: The different COVID-19 vaccines currently in use have features placing them closer to one or the other of these two extreme cases, V1 and V2, and insights on the importance of asymptomatic infection in a vaccinated population are of a major importance for the future planning of vaccination programmes. Our results give insights on how to best combine the use of the available COVID-19 vaccines, optimizing the reduction of hospitalizations. (C) 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University.
引用
收藏
页码:157 / 166
页数:10
相关论文
共 29 条
[1]   Condition-specific mortality risk can explain differences in COVID-19 case fatality ratios around the globe [J].
Aguiar, M. ;
Stollenwerk, N. .
PUBLIC HEALTH, 2020, 188 :18-20
[2]  
Aguiar M., 2020, Commun. Biomath. Sci., V3, P60, DOI 10.5614/cbms.2020.3.1.6
[3]   Critical fluctuations in epidemic models explain COVID-19 post-lockdown dynamics [J].
Aguiar, Maira ;
Van-Dierdonck, Joseba Bidaurrazaga ;
Mar, Javier ;
Cusimano, Nicole ;
Knopoff, Damian ;
Anam, Vizda ;
Stollenwerk, Nico .
SCIENTIFIC REPORTS, 2021, 11 (01)
[4]   The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study [J].
Aguiar, Maira ;
Stollenwerk, Nico .
VACCINES, 2020, 8 (04)
[5]   Modelling COVID 19 in the Basque Country from introduction to control measure response [J].
Aguiar, Maira ;
Ortuondo, Eduardo Millan ;
Bidaurrazaga Van-Dierdonck, Joseba ;
Mar, Javier ;
Stollenwerk, Nico .
SCIENTIFIC REPORTS, 2020, 10 (01)
[6]   Reproduction ratio and growth rates: Measures for an unfolding pandemic [J].
Aguiar, Maira ;
Van-Dierdonck, Joseba Bidaurrazaga ;
Stollenwerk, Nico .
PLOS ONE, 2020, 15 (07)
[7]   Dengvaxia: age as surrogate for serostatus [J].
Aguiar, Maira ;
Stollenwerk, Nico .
LANCET INFECTIOUS DISEASES, 2018, 18 (03) :245-245
[8]   Dengvaxia Efficacy Dependency on Serostatus: A Closer Look at More Recent Data [J].
Aguiar, Maira ;
Stollenwerk, Nico .
CLINICAL INFECTIOUS DISEASES, 2018, 66 (04) :641-642
[9]  
[Anonymous], EPIDEMIOLOGICAL SHAR
[10]  
[Anonymous], Transmission of COVID-19 by asymptomatic cases